<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16787">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107209</url>
  </required_header>
  <id_info>
    <org_study_id>MD68</org_study_id>
    <nct_id>NCT02107209</nct_id>
  </id_info>
  <brief_title>Low Cost Biological Lung Volume Reduction Therapy for Advanced Emphysema</brief_title>
  <acronym>BLVR</acronym>
  <official_title>Evaluation of Bronchoscopic Biological Lung Volume Reduction Therapy in Pulmonary Emphysema Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Higher Education</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical utility of bronchoscopic methods for achieving lung volume reduction has been
      evaluated in patients with advanced emphysema because these procedures are uniformly safer
      than surgical volume reduction. These include one-way valves, or bronchial occlusive devices
      to collapse emphysematous regions of lung and bronchial fenestration with bypass stents to
      improve expiratory flow, wire coils implants that compress the airway and thermal vapor
      ablation that causes an acute injury with subsequent fibrosis and reductions in volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic lung volume reduction (BioLVR): it is a novel endobronchial approach, which uses a
      Biological agents aiming to reduce lung volume by blocking off the most emphysematous areas
      with a rapidly polymerizing sealant. The mechanism of action involves resorption atelectasis
      from airway occlusion, subsequent airspace inflammation, and then remodeling. This
      remodeling will lead to scarring that induces contraction of lung parenchyma and functional
      volume reduction can be expected within 6-8 weeks. Biological lung volume reduction occurs
      independent of the presence or absence of collateral ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post-procedure lung volume reduction</measure>
    <time_frame>12 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from the baseline  high-resolution computed tomography (HRCT) volumetry Change from the baseline  Residual Volume/Total Lung Capacity from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-procedure Improvement in dyspnea and exercise capacity</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes from the  baseline post-bronchodilator forced expiratory volume at one second (FEV1) and forced vital capacity (FVC), diffusing capacity of lung for carbon monoxide  (DLCO), six-minute walk distance (6MWD),modified medical research council  (MMRC) dyspnea score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Bronchoscopic Lung volume reduction using Autologous blood.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchoscopic Lung volume reduction using Fibrin glue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 20 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopic Lung volume reduction</intervention_name>
    <description>Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment</description>
    <arm_group_label>Bronchoscopic Lung volume reduction using Autologous blood.</arm_group_label>
    <arm_group_label>Bronchoscopic Lung volume reduction using Fibrin glue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Emphysema determined by HRCT of the chest with:

               -  .Persistent symptoms (i.e. a baseline Modified Medical Research      Council
                  dyspnea (MRC) score of &gt;2 despite medical therapy).

               -  FEV1 /FVC &lt; 70% and FEV1 &lt;80% and &gt; 30% (moderate and sever airflow limitation
                  according to GOLD 2013).

               -  Hyperinflation (total lung capacity (TLC) &gt; 110% pred and residual volume (RV) &gt;
                  150% pred.

          2. Isolated bullae.

          3. Patients not candidate for or had refused lung volume reduction surgery.

          4. Age &gt; 40 yrs.

        Exclusion Criteria:

          1. Airflow limitation with FEV1 &lt; 30%.

          2. DLCO &lt; 20%.

          3. Current smoker.

          4. Patients not candidate for FOB.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Saad El-Morsi, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Chest Medicine Department, Faculty of Medicine, Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa Bakeer</last_name>
    <phone>00201005043663</phone>
    <email>mbekeer10@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chest Medicine Department, Faculty Of Medicine, Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Al-dakahliya</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa Bakeer</last_name>
      <phone>201005043663</phone>
      <email>mbekeer10@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 27, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mostafa Bakeer</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
